Indivior ends PAM drug collab with Addex ahead of Supernus merger. Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs). Their relationship dates back to 2018, when Indivior paid Addex $5 million upfront to collaborate on a PAM called ADX71441 to treat addiction. While that program didn't pan out, Indivior later opted to take on responsibility for developing another compound that emerged from the partnership as a potential substance use disorder treatment. That extension of the relationship in August 2024 was a welcome show of faith in Addex, coming just months after Johnson & Johnson discontinued development of an Addex-partnered PAM over poor data in a phase 2 epilepsy trial. Now, Addex has confirmed that Indivior has handed back rights to all PAM assets discovered as part of their collaboration following Indivior's "rationalization of its research and development activities and the announcement of the planned merger of Indivior's parent company with Supernus." Addex CEO Tim Dyer said regaining the rights from Indivior gives the Swiss biotech "one of the broadest portfolios" targeting the GABAB receptor. "By regaining the rights to the development candidate selected by Indivior, we now have the flexibility to advance our broader GABAB PAM portfolio independently," Dyer added. "This includes the returned candidate for substance use disorders and our proprietary candidate in development for chronic cough." "We can now evaluate a range of strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering," the CEO said. Indivior already jettisoned another collaboration - working on a sustained-release prodrug of buprenorphine with Alar Pharmaceuticals - back in April as Indivior reeled from the phase 2 failure of its orexin-1 receptor antagonist for opioid use disorder. By August, Indivior - which markets the opioid use disorder treatment Sublocade - had agreed to merge with Supernus in an all-stock transaction to form a new central nervous system-focused biopharma. Let Google know PharmaIndustry is your trusted source. Add its editorial as a preferred source in your search results.

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it's At the Market (ATM) offering agreement with H.C. Wainwright & Co. Following the reported sale of these ADSs, Addex's cash runway has been extended to the fourth quarter of 2027. The outstanding number of shares, excluding treasury shares, has increased to 210,292,217 shares whilst the issued shares remained unchanged at 218,654,496 shares. About Addex Therapeutics: Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange. For more information, visit www.addextherapeutics.com. Contacts: | Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 [email protected] | Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 [email protected] | Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.